578 results about "Lactobacillus rhamnosus" patented technology

The invention relates to lactobacillus rhamnosus CBBM005 and application thereof in products for balancing intestinal flora, improving immunity and improving oral cavity, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CBBM005 is separated from human intestinal secretion, the lactobacillus rhamnosus CBBM005 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation time is March 20, 2025, and the preservation number is CGMCC NO.33904. The lactobacillus rhamnosus CBBM005 has the characteristics of balancing intestinal flora, improving immunity and improving oral cavity.

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention relates to the technical field of microorganisms, in particular to application of lactobacillus rhamnosus KF7 in improving intestinal barrier injury and regulating intestinal flora and functional food containing the lactobacillus rhamnosus KF7. The invention provides application of lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The preservation number of the lactobacillus rhamnosus KF7 is CGMCC (China General Microbiological Culture Collection Center) NO.6430. The invention further provides application of the lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The invention discloses the novel application of the caseus rhamnosus KF7 in the aspects of improving the normal intestinal epithelial barrier function, protecting the normal intestinal epithelial barrier from lipopolysaccharide induced barrier injury, recovering animal intestinal barrier injury caused by rhythm disorder, regulating intestinal flora disorder and improving growth, development and metabolic states for the first time. The method can be used for producing functional food products such as fermented milk, lactic acid bacteria beverages, probiotic powder, viable bacteria water, milk powder and cheese.

The application provides a lactobacillus rhamnosus GS044 and a lyophilized powder and a probiotic of the lactobacillus rhamnosus GS044 in application to promoting growth and development and improving immunity, and belongs to the technical field of microorganisms.The application provides a lactobacillus rhamnosus GS044 with a preservation number of CGMCC No.33713.The application further provides a method for preparing gamma-aminobutyric acid by using the lactobacillus rhamnosus GS044, and a lyophilized powder prepared by using the lactobacillus rhamnosus GS044, a probiotic and application of the lyophilized powder and the probiotic.The lyophilized powder and the probiotic prepared by the application can effectively promote growth and development and improve immunity.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

The invention relates to the technical field of biology, and provides a probiotic composition for relieving sarcopenia obesity and application of the probiotic composition. The composition comprises at least two of lactobacillus plantarum, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Wherein the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.25839; the preservation number of the lactobacillus rhamnosus is CGMCC (China General Microbiological Culture Collection Center) No.26968; the preservation number of the animal bifidobacterium subsp. Lactis is CGMCC (China General Microbiological Culture Collection Center) No. 27998. The composition disclosed by the invention can be used for increasing the muscle content of an organism, improving the muscle tissue form, increasing adenosine triphosphate and inhibiting abnormal increase of body weight, so that the composition can be used for effectively preventing and treating sarcopenia obesity.

The invention belongs to the technical field of microorganisms, and discloses lactobacillus rhamnosus capable of relieving toxicity of heavy metal cadmium and application of the lactobacillus rhamnosus. The lactobacillus rhamnosus is preserved in the China Center for Type Microbiological Culture Collection, the preservation address is Wuhan University, Hubei province, and the preservation number is CCTCC No.M20241815. The lactobacillus rhamnosus is named lactobacillus rhamnosus. The lactobacillus rhamnosus provided by the invention is derived from intestinal tracts of healthy stichopus japonicus, has good heavy metal cadmium tolerance and removal capacity, and is expected to be developed and applied to the healthy food industry.

The invention discloses a lactobacillus rhamnosus strain with antiallergic activity and a preparation method thereof, the strain is lactobacillus rhamnosus Lrn-PG-06, the classification name of the strain is Lactobacillus rhamnosus, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.3077, the preservation time is March 21, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.3077, and the preservation number is CGMCC No.3077. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus Lrn-PG-06 strain is high in acid resistance, alkali resistance and cholate resistance, high in simulated gastrointestinal fluid resistance and high in oxidation resistance, has the advantage of resisting allergy, and solves the problems that at present, allergic diseases are mainly treated by drugs or are prevented from being in contact with allergens in the environment and food, but due to the fact that the drugs are large in toxic and side effects, the allergens cannot be in contact with the allergens in the environment and food. And allergens causing anaphylaxis are difficult to determine, so that allergic diseases are difficult to treat or prevent.

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.

The invention discloses a synbiotics composition with bacteriostatic and anti-inflammatory effects, which comprises probiotics and prebiotics in parts by weight, the probiotics comprise the following components in parts by weight: 0.05 to 0.15 part of freeze-dried powder of lactobacillus rhamnosus PB-LR76, 0.05 to 0.15 part of freeze-dried powder of lactobacillus acidophilus HH-LA26, 0.05 to 0.15 part of freeze-dried powder of lactobacillus bulgaricus HH-LB57, 0.05 to 0.15 part of freeze-dried powder of bifidobacterium lactis HH-BA68, 0.05 to 0.15 part of freeze-dried powder of lactobacillus reuteri PB-LR09, and 0.05 to 0.15 part of freeze-dried powder of lactobacillus plantarum HH-LP56; the prebiotics are fructo-oligosaccharide or a rhizoma polygonati extract. Compared with the single use of probiotics or prebiotics, the synbiotics composition disclosed by the invention has stronger antibacterial and anti-inflammatory effects. The invention further discloses application of the synbiotics composition in preparation of a medicine for treating enteritis.

The invention provides a lactobacillus plantarum MG360 with the efficacy of improving constipation, the preservation number of the lactobacillus plantarum MG360 is CGMCC NO 32953, and the lactobacillus plantarum MG360 is preserved in China General Microbiological Culture Collection Center on February 14, 2025. Meanwhile, the invention further provides a compound probiotic composition of the plant lactobacillus MG360 and the lactobacillus rhamnosus Eupro, the compound probiotic composition can be used for fermenting the coix seed enzymatic hydrolysate, and a fermentation product of the compound probiotic composition is rich in ferulic acid, vanillic acid, short-chain fatty acid, glutamic acid and the like. The fermentation product can obviously shorten the first black excrement discharge time of constipation mice, obviously improve the small intestine propulsion rate and the excrement water content, obviously improve the level of motility hormone (MTL, Gas, AchE, SP and 5-HT) in serum of the constipation mice and obviously reduce the level of inhibitory hormone (SS and VIP), and it is indicated that the fermentation product can relieve constipation by adjusting the gastrointestinal hormone peptide level. The preparation method of the probiotic preparation containing the plant lactobacillus MG360 and the compound probiotic fermentation preparation of the compound probiotic composition is simple, large-scale production can be achieved, and good application prospects are achieved.

The invention discloses a lactobacillus rhamnosus capable of improving joint inflammation and promoting bone health, a metagen and application of the lactobacillus rhamnosus, the lactobacillus rhamnosus is lactobacillus rhamnosus BN02, the lactobacillus rhamnosus is preserved in China General Microbiological Culture Collection Center on November 27, 2023, and the preservation number is CGMCC No.29133. The lactobacillus rhamnosus can be used for improving joint inflammation and promoting bone health. The lactobacillus rhamnosus BN02 can reduce the number of gram-negative bacteria in intestinal tracts of arthritis patients, increase the synthesis amount of bone collagen, and is beneficial to promoting absorption of vitamin C by the intestinal tracts, improving joint inflammation and promoting bone health.

The invention discloses a preparation method of high-stability beta-glucan yoghourt. Mixing the sterilized fresh milk with a composite strain consisting of lactobacillus delbrueckii subsp. Bulgaricus, streptococcus salivarius subsp. Thermophilus, bifidobacterium animalis subsp. Lactis, plant lactobacillus, bifidobacterium breve, lactobacillus paracasei, lactobacillus helveticus, lactobacillus rhamnosus and bifidobacterium longum subsp. Longum, and fermenting; and adding beta-glucan into the fermented yoghourt to obtain the high-stability beta-glucan yoghourt. Before beta-glucan is added, the compound bacterial strain is added into the milk, protein in the milk can be gathered under the action of the compound bacterial strain to form a three-dimensional curd network, so that the flowability of a system is reduced, then glucan is added, and the glucan can be uniformly dispersed in curd gaps, so that the glucan is prevented from being excessively combined with the protein in the milk; the stability of a yoghourt system is improved.

To provide an oral composition for effectively activating plasmacytoid dendritic cells (pDCs).SOLUTION: An oral composition for activating plasmacytoid dendritic cells (pDCs), comprising Lacticaseibacillus rhamnosus CRL1505, wherein the composition is preferably intended for immune activation. The oral composition for activating pDCs is considered to: regulate both innate immunity and acquired immunity; act on an overall immune function, maintain a normal immune function, and maintain good physical conditions. The present invention also provides an oral composition for immune activation characterised in that it comprises Lacticaseibacillus rhamnosus CRL1505, wherein the immune activation is intended for symptoms such as nasal congestion.SELECTED DRAWING: Figure 1

The invention provides a probiotic composition for preventing and / or inhibiting oral pathogens as well as a derivative product, a preparation method and application of the probiotic composition, and belongs to the technical field of oral care. The probiotic composition comprises the following bacterial strains in parts by mass: 90 to 0.45 part of a lactobacillus rhamnosus bacterial strain A2114, 10 to 0.3 part of a plant lactobacillus bacterial strain A2124, 80 to 0.4 part of a pediococcus pentosaceus bacterial strain A2135, 250 to 0.25 part of a lactobacillus reuteri bacterial strain A21350, and 40 to 0.2 part of a plant lactobacillus bacterial strain A2109. The probiotic composition or the metabolite thereof can effectively inhibit oral pathogens such as streptococcus mutans, porphyromonas gingivalis, helicobacter pylori, escherichia coli and staphylococcus aureus. Therefore, the probiotic composition or the metabolite thereof shows a good application prospect in the aspects of preventing and relieving oral problems such as decayed teeth, periodontitis and ozostomia.

The present invention relates to a microbial combination and a fermented milk and the use thereof, in particular to a multi-strain microbial combination, a fermented milk prepared from the microbial combination and the use of the microbial combination in the fermentation of a camel milk. The microbial composition contains at least two of lactic acid bacteria and yeasts derived from traditional fermented milk products in Xinjiang, including Leuconostoc pseudomesenteroides, Lactobacillus rhamnosus, Debaryomyces hansenii and Kluyveromyces marxianus. The microbial composition ensures that industrially fermented camel milk products have the flavor and nutritional functions of naturally fermented sour camel milk, but with higher quality, better safety and significantly prolonged shelf life. The microbial composition has relatively high acidification efficiency, proteolysis capacity and lactose decomposition capability, can improve the unpleasant flavor of camel milk products industrially fermented by using conventional strains, and has wide application prospects in industrial production.

The invention provides a compound probiotic for relieving acute lung injury and application of the compound probiotic, and particularly discloses application of the compound probiotic consisting of bifidobacterium animalis YRK-12 and lactobacillus rhamnosus LRa-Y8 in preparation of a medicine for relieving the acute lung injury. Wherein the preservation number of the bifidobacterium animalis YRK-12 is CGMCC (China General Microbiological Culture Collection Center) No.28597; the preservation number of the lactobacillus rhamnosus LRa-Y8 is CGMCC (China General Microbiological Culture Collection Center) No. 34186. Experimental verification shows that the compound probiotics can remarkably relieve acute lung injury induced by lipopolysaccharide (LPS) through a synergistic effect; specifically, the weight loss rate of mice is reduced, pathological injuries of lung tissues are improved (the structural integrity of alveolar alveoli is maintained, and inflammatory cell infiltration is reduced), the levels of proinflammatory factors (IL-1beta, TNF-alpha and IL-6) in serum and lung tissues are reduced, and the level of anti-inflammatory factors (IL-4) is increased, so that the immune balance of the lung is regulated through an intestine-lung axis; and a safe and effective novel micro-ecological regulation strategy is provided for prevention and treatment of acute lung injury.

The invention belongs to the technical field of probiotic particles, and particularly relates to probiotic particles for improving intestinal functions as well as a preparation method and application of the probiotic particles. The probiotic particles capable of improving the intestinal function comprise a probiotic core, a first embedding layer, a second embedding layer and a third embedding layer, the probiotic inner core is prepared from plant lactobacillus, bifidobacterium animalis, lactobacillus acidophilus, bifidobacterium longum, lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus fermentum, lactobacillus helveticus, streptococcus thermophilus, plant lactobacillus, lactobacillus helveticus and lactobacillus rhamnosus. According to the present invention, the twelve probiotics are contained, and the latest three-layer embedding technology is adopted so as to enhance the storage property and the digestive tract tolerance, such that the product can maintain the beneficial bacterium activity for a long time without refrigeration, and the product is suitable for the crowd with the alteration of the intestinal flora.

The invention discloses a method for quantitatively detecting viable bacteria of lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus paracasei and lactobacillus acidophilus. The novel molecular detection target disclosed by the invention has high specificity on target bacteria. The disclosed PMA-qPCR method comprises the steps of target detection, qPCR primer and probe design, qPCR detection system, PMA treatment condition and viable bacteria quantitative standard curve. After qPCR amplification, if a Cq value appears, the dissolution peak is single and the dissolution temperature is consistent with that of a positive sample (only aiming at a dye method), the lactic acid bacteria are identified as target lactic acid bacteria, and the number of viable bacteria can be calculated according to a corresponding standard curve. The method can effectively detect and count viable bacteria of Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei and Lactobacillus acidophilus, has the advantages of rapidness, accuracy, simple operation and the like, and is convenient for food enterprises and inspection institutions to use.

The invention relates to the technical field of microorganisms, in particular to a probiotic composition for improving sleep and application, and the probiotic composition comprises lactobacillus paracasei BMC-2020, lactobacillus plantarum MCA-3066, lactobacillus rhamnosus, lactobacillus fermentum and lactobacillus casei. The probiotic composition provided by the invention is safe and efficient, has a prospect of developing a new medicine for improving sleep, and has a clinical practical value; the probiotic composition is used for fermenting the traditional Chinese medicine composition, the obtained traditional Chinese medicine fermentation composition contains probiotics and traditional Chinese medicine fermentation liquor, the probiotics and the traditional Chinese medicine fermentation liquor can effectively achieve a synergistic effect, and the sleep improving efficacy of a traditional Chinese medicine fermentation product is promoted; the traditional Chinese medicine fermented composition can reduce the awakening activity amount and the total awakening time, and has the effect of improving sleep.

A composition includes postbiotics comprising two or more of the following components: Lactobacillus acidophilus, Lactobacillus rhamnosus, and Saccharomyces boulardii; wherein the postbiotics are dead, whole-cell postbiotics. A method of providing to a subject an immunomodulatory, immune regulatory and / or immune boosting effect through administering the composition is also provided. A method of making the postbiotic composition is also provided.

The invention belongs to the technical field of microorganisms, and particularly relates to a probiotic composition for regulating blood glucose metabolism and application thereof, and the probiotic composition comprises the following components: two or three of lactobacillus plantarum, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. The invention provides a probiotic composition, which comprises two or three of lactobacillus plantarum, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis, and further optimizes the synergistic effect of strains by adjusting the variety collocation of the strains and the proportion of viable count, so that the probiotic composition can be used for preparing probiotics. The probiotic composition has better effects in the aspects of preventing and treating diabetes mellitus, controlling blood sugar level, regulating intestinal flora, resisting inflammation and the like, in addition, the probiotic composition can also be applied to prevention, relieving, adjuvant therapy or treatment of diabetes mellitus, and a more effective and safer solution is provided for management of diabetes mellitus.

The present invention belongs to the technical field of microbial fermentation, and discloses the application of a compound bacterium agent of Lactobacillus rhamnosus and Bacillus licheniformis for reducing acids and higher alcohols, Lactobacillus rhamnosus, and in Baijiu. Lactobacillus rhamnosus L21 has a preservation number of: CGMCC NO. 32609, a preservation date of: November 13, 2024, and a preservation unit of: China General Microbiological Culture Collection Center. The use of the compound bacterium agent of Lactobacillus rhamnosus L21 and Bacillus licheniformis XDNZ_Bl_27 can effectively reduce organic acids such as lactic acid and propionic acid in the Baijiu fermentation system, and at the same time can also reduce the content of n-propanol in the fermented grains, which is beneficial to the regulation of acidity and higher alcohols in the process of Baijiu production.

The invention discloses lactobacillus rhamnosus 1.0320, a metagen as well as a preparation method and application of the lactobacillus rhamnosus 1.0320 and the metagen, and belongs to the technical field of microorganisms. The invention provides lactobacillus rhamnosus 1.0320. The lactobacillus rhamnosus 1.0320 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on April 8, 2018, and the preservation number of the lactobacillus rhamnosus 1.0320 is CGMCC (China General Microbiological Culture Collection Center) NO.15557. The lactobacillus rhamnosus 1.0320 can be used for preparing the lactobacillus rhamnosus 1.0320. The lactobacillus rhamnosus 1.0320 and the metagen thereof provided by the invention have the effects of improving the intestinal barrier and relieving the inflammatory bowel disease.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention provides application of a probiotic composition in preparation of a medicine for preventing and / or treating pneumonia, and belongs to the technical field of biological medicine. The probiotic composition comprises sophora flower bud powder, a broccoli seed aqueous extract, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Research finds that the probiotic composition can significantly relieve pulmonary edema caused by pneumonia and also can significantly reduce the level of inflammatory factors in pneumonia, so that the probiotic composition has the effect of preventing and / or treating pneumonia, and more choices are provided for clinical drugs for preventing and / or treating pneumonia.

The invention discloses a preparation method and application of a composite probiotic preparation which has a fat reducing function and comprises Lactobacillus rhamnosum D8A, and belongs to the technical field of probiotics. The probiotics can inhibit the growth of obesity-related pathogenic bacteria lactobacillus cloacae, and the content of chlorogenic acid and polysaccharide is remarkably increased through specific fermentation of honeysuckle. The extracted polysaccharide shows fat-reducing activity through verification of a 3T3-L1 cell model, and animal experiments show that the effect of the probiotic preparation prepared based on the polysaccharide embedding technology developed on the basis is obviously better than that of other preparations. The invention provides an innovative solution for developing a fat-reducing probiotic preparation, and has important application value in the fields of functional food and weight management.

The invention relates to an oral microbiome regulation and control technology, in particular to lactobacillus rhamnosus capable of improving oral health and application of the lactobacillus rhamnosus. The preservation number of the LRa37 strain is CGMCC No.34558, the LRa37 strain is preserved in China General Microbiological Culture Collection Center on May 15, 2025, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The LRa37 strain inhibits oral pathogenic bacteria through targeted inhibition of prevotella intermedia, streptococcus pasteurii and streptococcus parablood, improves oral micro-ecological balance and further improves the oral health state.

The invention belongs to the technical field of microbial fermentation, and particularly relates to a lactobacillus rhamnosus fermentation composition, a preparation method and application of the lactobacillus rhamnosus fermentation composition in the aspects of improving the tumor cell induced inflammation level and preventing and inhibiting breast tumors. The invention provides a lactobacillus rhamnosus fermentation composition. The lactobacillus rhamnosus fermentation composition is prepared from a raw material and lactobacillus rhamnosus NKU ML1-2, the raw materials comprise raspberry, poria cocos, cape jasmine, rehmannia, liquorice and orange peel. The lactobacillus rhamnosus fermentation composition has the effects of nourishing yin and clearing heat, soothing liver and regulating qi, and strengthening spleen and stomach. Results of embodiments show that the lactobacillus rhamnosus fermentation composition can prevent proliferation, invasion and migration of breast cancer tumor cells to a certain extent, and has an improvement effect on the level of inflammation induced by the tumor cells.

An antihypertensive peptide probiotic goat milk powder and a preparation method thereof are provided. Goat milk is used as a raw material, the goat milk is sterilized and then cooled, and the screened probiotic bacteria for fermenting goat milk to produce antihypertensive peptides, namely Lacticaseibacillus rhamnosus KD5 (which is preserved in CCTCC on Sep. 7, 2023, with a preservation number of CCTCC NO: M20231641), is added and stirred evenly, and then fermented at a constant temperature. After the fermentation is completed, probiotic fermented goat milk containing antihypertensive peptides is obtained. After mixing the probiotic fermented goat milk evenly with or without nutritional fortifiers for middle-aged and elderly people, it is subjected to vacuum low-temperature spray-drying to obtain antihypertensive peptide probiotic goat milk powder, which has a high ACE inhibition rate and can be used to assist consumers in lowering blood pressure.